TY - JOUR T1 - B and T cell responses after a third dose of SARS-CoV-2 vaccine in Kidney Transplant Recipients JF - medRxiv DO - 10.1101/2021.08.12.21261966 SP - 2021.08.12.21261966 AU - Eva Schrezenmeier AU - Hector Rincon-Arevalo AU - Ana-Luisa Stefanski AU - Alexander Potekhin AU - Henriette Staub-Hohenbleicher AU - Mira Choi AU - Friederike Bachmann AU - Vanessa Pross AU - Charlotte Hammett AU - Hubert Schrezenmeier AU - Carolin Ludwig AU - Bernd Jahrsdörfer AU - Andreia C. Lino AU - Kai-Uwe Eckardt AU - Katja Kotsch AU - Thomas Dörner AU - Klemens Budde AU - Arne Sattler AU - Fabian Halleck Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/08/13/2021.08.12.21261966.abstract N2 - Background Accumulating evidence suggests that solid organ transplant recipients, as opposed to the general population, show strongly impaired responsiveness towards standard SARS-CoV-2 mRNA-based vaccination, demanding alternative strategies for protection of this vulnerable group.Methods In line with recent recommendations, a third dose of either heterologous ChAdOx1 (AstraZeneca) or homologous BNT162b2 (BioNTech) was administered to 25 kidney transplant recipients (KTR) without humoral response after 2 doses of BNT162b2, followed by analysis of serological responses and vaccine-specific B- and T-cell immunity.Results 9/25 (36%) KTR under standard immunosuppressive treatment seroconverted until day 27 after the third vaccination, while one patient developed severe COVID-19 infection immediately after vaccination. Cellular analysis seven days after the third dose showed significantly elevated frequencies of viral spike protein receptor binding domain specific B cells in humoral responders as compared to non-responders. Likewise, portions of spike-reactive CD4+ T helper cells were significantly elevated in seroconverting patients. Furthermore, overall frequencies of IL-2+, IL-4+ and polyfunctional CD4+ T cells significantly increased after the third dose, whereas memory/effector differentiation remained unaffected.Conclusions Our data suggest that a fraction of transplant recipients benefits from triple vaccination, where seroconversion is associated with quantitative and qualitative changes of cellular immunity. At the same time, the study highlights that modified vaccination approaches for immunosuppressed patients still remain an urgent medical need.Significance statement Protection of solid organ transplant recipients against SARS-Cov-2 by vaccination remains an unmet need given the low immunogenicity of available vaccines in the presence of immunosuppression. Administration of a third dose to 25 kidney transplant recipients (KTR) resulted in seroconversion in 36% of patients, associated with significant quantitative and functional changes within the spike-antigen-specific B-cell- and CD4+ T-helper cell compartment. Our data support the need for individual humoral monitoring of immunosuppressed individuals after vaccination as well as continued efforts to adapt vaccination protocols for this at-risk group.Competing Interest StatementThe authors have declared no competing interest.Funding StatementES was funded by the Federal Ministry of Education and Research (BMBF) grant (BCOVIT, 01KI20161) and is enrolled in the Charite Clinician Scientist Program funded by the Charite Universitaetsmedizin Berlin and the Berlin Institute of Health. ALS is funded by a scholarship of the German Society of Rheumatology. KK received funding by the Sonnenfeldstiftung Berlin, Germany. TD is grant holder of the Deutsche Forschungsgemeinschaft (Do491/7 5, 10 2, 11 1, Transregio 130 TP24). KK was supported by grants from the Deutsche Forschungsgemeinschaft (KO-2270/71, KO 2270/4 1). AS, KK and FH received project funding from Chiesi GmbH. HRA holds a scholarship of the COLCIENCIAS scholarship No. 727, 2015. HS receives funding by the Ministry for Science, Research and Arts of Baden Wuerttemberg, Germany and the European Commission (HORIZON2020 Project SUPPORT E, 101015756).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All participants gave written informed consent for sample collection according to the approval of the ethics committees of the Charite Universitaetsmedizin Berlin (EA2/010/21, EA4/188/20), of the county of Saxony-Anhalt (EA7/21) and the University of Greifswald (BB019/21).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll original data are available upon request. ER -